Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9020915 | 1.00 | CYP2D6 (0.42) | CYP2D6CYP2C9CYP2C19SOAT1ALDH1A1 | |
| Butyric Acid SCHEMBL11237544 | 0.89 | FFAR3 (0.38) | CYP2D6CYP2C9CYP2C19ALDH1A1TSHR | |
| SCHEMBL9678720 | 0.83 | ENO1 (0.34) | CYP2D6CYP2C9CYP2C19TSHRLMNA | |
| SCHEMBL800030 | 0.82 | SOAT1 (0.46) | CYP2D6CYP2C9SOAT1ALDH1A1NPSR1 | |
| SCHEMBL29250921 | 0.81 | CYP2C9 (0.42) | CYP2D6CYP2C9CYP2C19SOAT1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11056611 | 0.80 | SOAT1 (0.44) | CYP2D6CYP2C9SOAT1ALDH1A1NPSR1 | |
| SCHEMBL6691893 | 0.80 | SOAT1 (0.44) | CYP2D6CYP2C9SOAT1ALDH1A1NPSR1 | |
| SCHEMBL5962754 | 0.76 | MEN1 (0.42) | TSHRLMNAMEN1HPGDBLM | |
| SCHEMBL3903608 | 0.76 | MEN1 (0.42) | TSHRLMNAMEN1HPGDBLM | |
| SCHEMBL17616389 | 0.76 | SOAT1 (0.41) | CYP2D6CYP2C9SOAT1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644612-B1 | Method for producing sanshool | TSUMURA & CO (JP) | 2016-01-06 | — | — | EP | claimed |
| US-8877953-B2 | Method for producing sanshool | TSUMURA & CO. (JP) | 2014-11-04 | — | — | US | claimed |
| US-20130261327-A1 | METHOD FOR PRODUCING SANSHOOL | TSUMURA & CO. (JP) | 2013-10-03 | — | — | US | claimed |
| EP-2644612-A1 | Method for producing sanshool | TSUMURA & CO. (JP) | 2013-10-02 | — | — | EP | claimed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240217983-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-115996914-B | Novel heterocyclic compound and salt thereof, and luminescent substrate composition | 国立大学法人电气通信大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20240158359-A1 | HYDROLYSIS-RESISTANT ESTERS FOR DRUG AND IMAGING AGENT DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| WO-2024102730-A1 | LIPIDS AND NANOPARTICLE COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4320129-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-4310545-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4305959-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4281019-A | 4-[(Unsaturated or cyclopropylated alkyl)amino]phenyl compounds useful as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4259352-A | 4-[Cycloalkyl- or cycloalkenyl-amino(cycloalkyl- or cycloalkenyl-alkenyl)amino]phenyl compounds, useful as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4205085-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4107188-A | FOR DECREASING LIPID LEVELS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261327-A1 | METHOD FOR PRODUCING SANSHOOL | SCO2, FTH1, CNKSR1 | CYP2D6 2937/4885CYP2C9 1646/4885CYP2C19 2716/4885 |
| US-20240158359-A1 | HYDROLYSIS-RESISTANT ESTERS FOR DRUG AND IMAGING AGENT DELIVERY | ABCG2, BLVRB, CES1 | CYP2D6 272/4885CYP2C9 259/4885CYP2C19 499/4885 |
| US-20240217983-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | CYP2D6 2317/4885CYP2C9 2350/4885CYP2C19 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.